Founded as a spin-off from Medtronic in 2007, Inspire Medical Systems focuses on alternative treatments for moderate to severe obstructive sleep apnea, particularly for patients who cannot tolerate traditional Continuous Positive Airway Pressure (CPAP) therapy. The company's core offering is a proprietary, closed-loop neurostimulation system consisting of a pressure-sensing lead, a neurostimulator, and a stimulation lead, which are managed via a patient remote and mobile application. Inspire generates the vast majority of its revenue from the sale of these systems directly to hospitals and surgical centers. While its primary market is the United States, the company is expanding its geographic footprint across Europe and Asia. The Inspire therapy is supported by clinical data and is covered by most major commercial insurance plans, including Medicare.
